Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9GRK

Cdc42 Binding peptide (W14A)

Summary for 9GRK
Entry DOI10.2210/pdb9grk/pdb
DescriptorPRO-SER-ILE-CYS-HIS-VAL-HIS-ARG-PRO-ASP-TRP-PRO-CYS-ALA-TYR-ARG (1 entity in total)
Functional Keywordspeptide; cdc42 binding., de novo protein
Biological sourcesynthetic construct
Total number of polymer chains1
Total formula weight1941.24
Authors
Mott, H.R.,Murphy, N.P.,Owen, D. (deposition date: 2024-09-11, release date: 2026-02-11)
Primary citationMurphy, N.P.,Tetley, G.J.N.,Revell, J.,Mott, H.R.,Owen, D.
Cyclized Peptide Inhibitors of the Small G Protein Cdc42 Mimic Binding of Effector Proteins.
Biochemistry, 2026
Cited by
PubMed Abstract: The Ras superfamily of small GTPases are challenging targets for therapeutic inhibition, partially due to a lack of pockets amenable to small molecule inhibition. Our previous work identified high-affinity cyclized peptide binders of Cdc42, a member of the Rho family of small GTPases, capable of inhibiting activity. To further optimize these Cdc42 inhibitors, we have engineered modifications to the best sequence available from the original maturation and screened the ability of these third-generation peptides to compete with Cdc42-effector interactions. Improvements in affinity were achieved by single amino acid substitutions at several residue positions. We present the structure of one of these nanomolar affinity, cyclized peptides in complex with Cdc42. The structure reveals that the peptide binds in a β-hairpin conformation to create an extension of the β-sheet of the GTPase Rossman fold, acting as a structural mimic of native Cdc42 effectors. We additionally elucidate the NMR structures of four unbound C-terminal alanine variants and employ both the bound and unbound structures to inform the rational design of substituted peptide inhibitors. Overall, this study expands our understanding of how Ras GTPases can be targeted, by demonstrating a rare example of an inhibitor binding contiguously with a surface of β-strand of the small G protein, which illustrates an innovative avenue for noncovalent therapeutic design.
PubMed: 41566164
DOI: 10.1021/acs.biochem.5c00616
PDB entries with the same primary citation
Experimental method
SOLUTION NMR
Structure validation

248942

PDB entries from 2026-02-11

PDB statisticsPDBj update infoContact PDBjnumon